3 Reasons It's Smart to Buy Celgene's Stock Now
Celgene Corp. (NASDAQ: CELG) shares nose-dived in October following a trial failure and third-quarter financials that failed to impress. However, there are good reasons investors ought to consider adding Celgene to portfolios, including upcoming data for cancer trials, a promising potential new drug launch in 2018, and a bulletproof balance sheet.
In December, industry leaders will get together to discuss the latest in blood cancer research at the annual American Society of Hematology (ASH) conference.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
